Variablea | Baseline (n = 3495) | COVID-19 pandemic (n = 1014) | Post- Pandemic (n = 1008) | P |
---|---|---|---|---|
Male | 68.4 (2389) | 60.0 (608) | 55.2 (556) |  < 0.005 |
Age, median (IQR), y | 71 (60–82) | 80 (68–89) | 77 (65–88) |  < 0.005 |
Age groups | ||||
 18–59 years | 24.4 (852) | 12.4 (126) | 17.8 (179) |  < 0.005 |
 60–69 years | 23.1 (807) | 13.7 (139) | 15.9 (160) |  < 0.005 |
 ≥ 70 years | 52.5 (1836) | 73.9 (749) | 66.4 (669) |  < 0.005 |
Comorbidity, % (no.) | ||||
 Any (at least one) | 54.6 (1909) | 70.8 (718) | 64.0 (645) |  < 0.005 |
 Diabetes mellitus | 14.3 (500) | 23.2 (235) | 25.3 (255) |  < 0.005 |
 Liver disease | 5.0 (176) | 3.9 (40) | 5.9 (59) | 0.137 |
 Stroke | 11.8 (412) | 26.1 (265) | 18.0 (181) |  < 0.005 |
 Malignancy | 10.2 (357) | 12.6 (128) | 12.0 (121) | 0.050 |
 Renal disease | 4.9 (173) | 9.6 (97) | 7.7 (78) |  < 0.005 |
 Chronic pulmonary disease | 14.6 (511) | 13.2 (134) | 9.9 (100) |  < 0.005 |
 Congestive heart failure | 8.0 (280) | 13.5 (137) | 12.4 (125) |  < 0.005 |
 Rheumatological disease | 1.9 (67) | 1.8 (18) | 1.4 (14) | 0.540 |
 HIV infection | 0.4 (14) | 0.6 (6) | 0.6 (6) | 0.600 |
Charlson comorbidity index ≥ 4 | 53.0 (1852) | 75.3 (764) | 66.4 (669) |  < 0.005 |
Type of pneumococcal disease | ||||
 IPDWP | 7.4 (259) | 3.6 (37) | 4.4 (44) |  < 0.005 |
 IPP | 12.9 (451) | 4.7 (48) | 8.0 (81) |  < 0.005 |
 NIPP | 79.7 (2785) | 91.6 (929) | 87.6 (883) |  < 0.005 |
Pneumococcal disease by site | ||||
 Bacteremia | 17.3 (603) | 6.8 (69) | 10.1 (102) |  < 0.005 |
 Pneumonia | 92.6 (3236) | 96.4 (977) | 95.6 (964) |  < 0.005 |
 Pleural empyema | 2.2 (78) | 1.0 (10) | 2.0 (20) | 0.040 |
 Meningitis | 1.9 (66) | 1.2 (12) | 1.4 (14) | 0.227 |
Viral coinfection | ||||
 Influenza | 8.8 (309) | 1.2 (12) | 12.1 (122) |  < 0.005 |
 COVID-19 | - | 9.0 (91) | 10.9 (110) | 0.987 |